Genmab A (GMAB) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Genmab A  (NASDAQ: GMAB)


Genmab A's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Genmab A's ROA in the fourth quarter of 2025?
Genmab A achieved a return on average assets (ROA) of 18.05 % in its fourth quarter of 2025, this is above GMAB's average return on assets of 14.78%.
Genmab As assets during the 12 months ending in the fourth quarter of 2025 are valued at $7 billion

ROA has improved compared to 5.94% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 139 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 967.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Total Assets Change -78.78 % 111.74 % -86 % 174.53 % 71.81 %
Y / Y Net Income Change 374.38 % - 24.16 % - -59.31 %
Net Income (TTM) in million 1,299 539 763 698 747
Return On Assets (TTM) 18.05 % 5.94 % 10.35 % 7.8 % 10.84 %
GMAB's Total Ranking # 967 # # # # 294
Total Assets (TTM) in million 2,023 12,873 1,020 12,873 9,532
Seq. Total Assets Change -84.29 % 1162.35 % -92.08 % 35.06 % 56.78 %
Seq. Net Income Change - - - - -9.49 %

GMAB's 5 Years Annual ROA >> Back to GMAB Management Effectiveness >> Compare GMAB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 56
Sector # 140
Overall # 961

Return On Assets Statistics
High Average Low
20.96 %
14.78 %
7.48 %
(Dec 31 2020)   (Dec 31 2025)





Financial Statements
Genmab A's Assets $ 2,023 million GMAB's Balance sheet
Genmab A's Income $ 963 million Quarterly GMAB's Income Statement
GMAB's Income by Division See GMAB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 131.97 % 30.86 % 31.17 % 48.01 % 7.85 %
Total Assets in million 22,090 9,523 7,277 5,548 3,748
Y / Y Net Income Change -15 % 79.56 % -18.26 % 64.1 % -35.42 %
Net Income in million 963 1,133 631 772 470
Annual Return On Assets 4.36 % 11.9 % 8.67 % 13.91 % 12.55 %

GMAB's 5 Years Annual ROA >> Back to GMAB Management Effectiveness >> Compare GMAB ROA to its Competitors



Comment on GMAB's ROA in the fiscal year ending 2025
In the fiscal year 2025 Genmab A's ROA decreased compared to previous year to 4.36 %, due to deterioration of net income -15 % to $963.00 million, from $1,133.00 million a year ago, as GMAB's assets were $22,090.00 million.


More Return On Assets Ratios
GMAB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GMAB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GMAB's Competitors
Subscribers only: Roa for Genmab A's Suppliers
Subscribers only: Return On Assets for GMAB's Customers

You may also want to know
GMAB's Roi GMAB's Inventory Turnover Ratio GMAB's Growth Rates GMAB's Dividend Comparisons
GMAB's Profitability Ratios GMAB's Asset Turnover Ratio GMAB's Dividend Growth
GMAB's Roe GMAB's Valuation Ratios GMAB's Financial Strength Ratios GMAB's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Pulmatrix Inc   48.84 %
Earth Science Tech Inc   45.81 %
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %
Qhslab Inc   25.12 %
Medpace Holdings Inc   25.07 %
Mettler toledo International Inc   25.07 %
Compugen Ltd  22.57 %
Lifemd Inc   21.39 %
Catalyst Pharmaceuticals Inc   21.24 %
Iradimed Corporation  20.83 %
Incyte Corporation  20.70 %
Transmedics Group Inc   20.34 %

Date modified: 2026-07-07T11:25:19+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.